R&D Update: How Can Companies Improve on Existing Antiangiogenesis Agents?

Table of Contents

• Executive Summary
  • Strategic Implications
  • Stakeholder Implications
• Introduction
• Biology of Tumor Angiogenesis
  • VEGF Pathway
  • Integrin Signaling
  • PDGFR
  • Cell Hypoxia
• Antiangiogenic Agents Approved to Treat Cancer
  • Genentech' s Avastin
  • Bayer' s Nexavar
  • Pfizer' s Sutent
• Emerging Antiangiogenesis Agents to Treat Cancer
  • Emerging Small-Molecule Antiangiogenic Drugs
    • Celgene' s Thalidomide Derivatives
    • Merck' s Cilengitide
    • GlaxoSmithKline' s Pazopanib
    • AstraZeneca' s Zactima
    • AstraZeneca' s Cediranib
  • Emerging Large-Molecule Antiangiogenic Drugs
    • Regeneron/Sanofi -Aventis' s Afl ibercept
    • PDL BioPharma/Biogen Idec' s Volociximab
    • UCB/ImClone' s CDP-791
    • Amgen' s AMG-386
• Improving on Antiangiogenesis Agents
  • Improving the Effi cacy of Antitumor Agents
  • Preventing Resistance to Antiangiogenic Drugs
• Outlook

Tables:

• 1. Major Angiogenic Growth Factors
• 2. Key Angiogenesis Inhibitors
• 3. Antiangiogenic Agents Approved for the Treatment of Cancer
• 4. Emerging Small-Molecule Antiangiogenic Agents
• 5. Emerging Large-Molecule Antiangiogenic Agents

Figures:

• 1. The Angiogenic Process
• 2. The Role of mTor in the Regulation of HIF-1ƒ¿ and Angiogenesis